TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17334580
Drug: Dengue antibody
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue antibody prevalence
Study: 15334857
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 U subcutaneously every 12 hours
Study: 15334857
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 U subcutaneously every 8 hours
Study: 11710505
Drug: Methylprednisolone (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (plus an antiviral agent?)
Study: 11710505
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for viral inflammation
Study: 9024022
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate salt 12.5 mg
Study: 9024022
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate salt 25 mg
Study: 9024022
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate salt 50 mg
Study: 7908187
Drug: Intravenous beta‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta‐blocking agents
Study: 7908187
Drug: Glucose‐insulin‐potassium (GIK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose‐insulin‐potassium (GIK) therapy
Study: 7908187
Drug: Newer anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer anticoagulant and antithrombotic agents (hirudin and Hirulog)
Study: 7908187
Drug: Newer thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer thrombolytic drugs (recombinant plasminogen activator - r‐PA)
Study: 7908187
Drug: Surfactant and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant and emulsifying agents (Rheothrx)
Study: 24382836
Drug: Active Low-Level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Low-Level Laser Therapy (LLLT)
Study: 24382836
Drug: Placebo Low-Level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Low-Level Laser Therapy (LLLT)
Study: 8181024
Drug: Thiazide-type diuretic
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-type diuretic or low-dose loop diuretic
Study: 8181024
Drug: Large-dose loop
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose loop diuretic combined with thiazide-type diuretic
Study: 8181024
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous loop diuretic; short-term infusion of a loop diuretic; intensified combination oral diuretic therapy; intravenous positive inotropic therapy; ultrafiltration or dialysis
Study: 2691821
Drug: 312 g
Normalized name: BENZALKONIUM CHLORIDE 0.312 g in 240 mL TOPICAL SOLUTION [VitaVie]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 312 g of carbohydrate (H)
Study: 2691821
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g of carbohydrate (L)
Study: 2691821
Drug: 156 g
Normalized name: MENTHOL, UNSPECIFIED FORM 0.156 g TOPICAL PATCH [BLACK ICE MEDICATED PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 156 g of carbohydrate (M)
Study: 2691821
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of carbohydrate (P)
Study: 4557308
Drug: BX24 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX24 300 mg daily
Study: 4557308
Drug: BX24 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX24 600 mg daily
Study: 4557308
Drug: BX24 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX24 1200 mg daily
Study: 4557308
Drug: BX24 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX24 300 mg daily with zinc sulphate 660 mg daily
Study: 4557308
Drug: BX24 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX24 300 mg daily without zinc sulphate
Study: 4557308
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A 50,000 units daily
Study: 28766349
Drug: G-CSF administered
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administered at 10:00
Study: 28766349
Drug: G-CSF administered
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administered at 14:00
Study: 20732799
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones group (200 mg of Glycine max, 80 mg of isoflavone)
Study: 12972984
Drug: Low-dose right
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose right unilateral electroconvulsive therapy (approximately 2.25 times seizure threshold)
Study: 12972984
Drug: High-dose right
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose right unilateral electroconvulsive therapy (greater than 2.25 times seizure threshold)
Study: 12972984
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral electroconvulsive therapy (both doses)
Study: 10940089
Drug: Naratriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan (2.5 mg orally)
Study: 10940089
Drug: Sumatriptan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (50 mg orally)
Study: 9009937
Drug: S&G/block (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&G/block (1% lidocaine bilateral GPN blocks)
Study: 9009937
Drug: S&G (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&G (2% viscous lidocaine swish and gargle)
Study: 9009937
Drug: S&G/spray (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&G/spray (2% viscous lidocaine swish and gargle + 10% lidocaine spray)
Study: 7932402
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (ampicillin, gentamicin and clindamycin)
Study: 30099402
Drug: Guideline-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based physiotherapy treatment (control)
Study: 26632161
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) administration of eptifibatide
Study: 26632161
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of eptifibatide
Study: 11115156
Drug: Alitretinoin gel
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin gel (0.05% or 0.1% applied twice daily for the first 2 weeks and up to 4 times daily thereafter)
Study: 11115156
Drug: Alitretinoin gel
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin gel
Study: 9154995
Drug: Angiotensin-II (A-II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II (A-II) at pressor doses (8.44 ng/kg/min)
Study: 9154995
Drug: Angiotensin-II (A-II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II (A-II) at subpressor doses (0.62 ng/kg/min)
Study: 8425695
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA), 3 mg.kg‐1.day‐1
Study: 30243294
Drug: Propofol/remifentanil-based total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil-based total intravenous anesthesia (TIVA group)
Study: 24445147
Drug: Capecitabine (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1)
Study: 24445147
Drug: Capecitabine (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1) + Cisplatin (70 mg/m² intravenously on day 1)
Study: 20691266
Drug: PfCS102 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfCS102 (30 μg, twice)
Study: 11286039
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral sumatriptan
Study: 8972000
Drug: Sak42D (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sak42D (15 mg each, double bolus, 30 min apart)
Study: 8972000
Drug: rt‐PA (accelerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA (accelerated weight-adjusted, maximum of 100 mg over 90 min)
Study: 1600703
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (0.3 U kg‐1, 0.6 U kg‐1, 0.8 U kg‐1)
Study: 1600703
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (4 U)
Study: 1600703
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (6 U)
Study: 2861219
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg procaterol
Study: 2861219
Drug: 0.10 mg
Normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg procaterol
Study: 27437937
Drug: Spent over
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spent over $500 for drugs and alcohol in the past month
Study: 19008171
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous oxygen therapy (maximal flow rate of 2 L/min)
Study: 15705022
Drug: Cetylated fatty
Normalized name: Cetyl Alcohol
DrugBank: Cetyl alcohol (DB09494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetylated fatty acid (CFA) topical cream applied twice per day for 30 days
Study: 15705022
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical cream
Study: 10472228
Drug: Ropivacaine (285
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (285 mg)
Study: 1867580
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral intake of fluids (water, tea or coffee with sugar) without limitation of quantity
Study: 7052613
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) administered subcutaneously equivalent to 5 x 10^8 lymphocytes, given twice at one week intervals and then every four weeks thereafter.
Study: 25200559
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (RYGB) plus optimised clinical treatment (OCT)
Study: 25200559
Drug: Optimised clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised clinical treatment (OCT) alone
Study: 17725934
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of lorazepam (n=47)
Study: 15185267
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy for bulimia nervosa
Study: 2565346
Drug: L-dopa (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (small repeated doses)
Study: 2565346
Drug: L-dopa (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (small repeated doses) + haloperidol 15 mg
Study: 100866
Drug: i.v. TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TRH infusion (0.66 mg/hour) for 3 hours
Study: 16086715
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg
Study: 26407587
Drug: Hypoglycemic night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic night (PG target of 2.7-2.8 mmol/L maintained for 15 min)
Study: 26407587
Drug: Normoglycemic night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemic night (PG maintained at 5.0-7.0 mmol/L)
Study: 23704674
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (irrespective of group)
Study: 21802658
Drug: remifentanil (MOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (MOR agonist)
Study: 17615281
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg three times a day for 24 hours)
Study: 11936460
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine excretion (inland territory)
Study: 11936460
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine excretion (sea level)
Study: 11936460
Drug: Median urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median urinary iodine excretion (inland villages)
Study: 11936460
Drug: Median urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median urinary iodine excretion (Crotone)
Study: 11936460
Drug: Median urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median urinary iodine excretion (Reggio Calabria)
Study: 7769501
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g purified fish oil once a day for 6 months
Study: 28749254
Drug: Mixed training
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed training (two moderate and two high-intensity sessions weekly)
Study: 27609854
Drug: INSD ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSD ketamine (1 mg/kg)
Study: 27609854
Drug: IN fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN fentanyl (1.5 μg/kg)
Study: 25917674
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine (Rotarix)
Study: 25917674
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (Tootsweet)
Study: 8558644
Drug: Adjuvant CMV
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMV chemotherapy (cisplatin, methotrexate, vinblastine)
Study: 8558644
Drug: CMV chemotherapy
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV chemotherapy for salvage after relapse
Study: 1869388
Drug: Tobramycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (100 mg)
Study: 7041150
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment with topical chemotherapy and hydrotherapy
Study: 29396217
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment
Study: 31242190
Drug: Combined water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined water treatment, sanitation, and handwashing (WSH)
Study: 24480899
Drug: 7-day intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day intensive cognitive therapy for PTSD
Study: 24480899
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of standard weekly cognitive therapy
Study: 24480899
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of weekly emotion-focused supportive therapy
Study: 21842157
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg d,l‐methamphetamine
Study: 19679580
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (loading 3 microg kg(‐1) h(‐1) for 10 min; maintenance 0.2 microg kg(‐1) h(‐1) for 60 min)
Study: 19679580
Drug: Moderate-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose dexmedetomidine (loading 6 microg kg(‐1) h(‐1) for 10 min; maintenance 0.4 microg kg(‐1) h(‐1) for 60 min)
Study: 19679580
Drug: Dexmedetomidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (both doses)
Study: 17430414
Drug: Patients' daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' daily ratings of mood and functional impairment
Study: 17430414
Drug: Patients' daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' daily ratings of mood
Study: 12167446
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg) plus dexamethasone (8 mg)
Study: 10539742
Drug: Sitostanol powder
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol powder (1 g)
Study: 10539742
Drug: Sitostanol in
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol in lecithin micelles (700 mg)
Study: 10539742
Drug: Sitostanol in
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol in lecithin micelles (300 mg)
Study: 7424927
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg epinephrine hydrochloride
Study: 7424927
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg epinephrine hydrochloride
Study: 7424927
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg epinephrine hydrochloride
Study: 7424927
Drug: Control (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.1 mg and 0.3 mg)
Study: 31699052
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia combined with TAP block (40 mL of 0.375% ropivacaine)
Study: 30113724
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (80 mg)
Study: 30113724
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (120 mg)
Study: 30113724
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (180 mg)
Study: 27352504
Drug: Moxa salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxa salt packets at Zhongwan (CV 12) combined with tropisetron hydrochloride (5 mg)
Study: 27352504
Drug: Tropisetron hydrochloride
Normalized name: tropisetron hydrochloride
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron hydrochloride (5 mg)
Study: 23237204
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy in addition to orthoses therapy and home orientations
Study: 23237204
Drug: Orthoses therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthoses therapy and home orientations
Study: 20302573
Drug: UVB-LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB-LED therapy (high-dose group)
Study: 20302573
Drug: UVB-LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB-LED therapy (low-dose group)
Study: 15345158
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg after induction and placebo at 12 h postoperatively
Study: 15345158
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg after induction and 1.25 mg at 12 h postoperatively
Study: 15345158
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg plus Metoclopramide 10 mg after induction and droperidol 1.25 mg at 12 h postoperatively
Study: 11594643
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise programme (cycling for up to 30 minutes three times weekly for 24-36 sessions over 12 weeks)
Study: 2819572
Drug: One-day diet
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day diet control and oral dulcolax
Study: 811350
Drug: Abdominal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal radiation therapy alone
Study: 811350
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiation therapy and chlorambucil
Study: 28404609
Drug: Active moxibustion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active moxibustion plus placebo gel
Study: 28404609
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium gel plus placebo moxibustion
Study: 23703599
Drug: Intravenous prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prophylactic ramosetron 0.3mg (Control)
Study: 19407454
Drug: Pardoprunox (0.3‐42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pardoprunox (0.3‐42 mg/day)
Study: 19407454
Drug: Pardoprunox (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pardoprunox (up to 18 mg/day) with intermediate steps
Study: 14625336
Drug: 8 days
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Study: 14625336
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Study: 14625336
Drug: 8 days
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 days of antibiotic therapy (among patients with recurrent infections)
Study: 14625336
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of antibiotic therapy (among patients with recurrent infections)
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g) + 0 mg alpha-tocopheryl acetate (placebo)